Mesalazine is safe for the treatment of IBD [3]

Gut

Volumn 53, Issue 1, 2004, Pages 155-

  D'Haens, G ^a   Van Bodegraven, A A ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; MESALAZINE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; ENTERITIS; HUMAN; INCIDENCE; INTERSTITIAL NEPHRITIS; LETTER; NAUSEA; OLIGOSPERMIA; PRIORITY JOURNAL; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; SULFASALAZINE;

EID: 0347722481     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.53.1.155     Document Type: Letter

References (9)

1. Das KM, Eastwood MA, McManus JP, et al. Adverse reactions during solicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973;289:491-5.
2. Forbes A. Clinicians' guide to inflammatory bowel disease. London: Chapman and Hall, 1997.
3. th UEGW, Bruxelles. Gut 2000;(suppl).
4. World MJ, Stevens PE, Ashton MA, et al. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 1996,11:614-21.
5. Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1-6.
6. Marteau P, Nelet F, Le Lu M, et al. Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther 1996;10:949-56.
7. Dew MJ, Harries AD, Evans BK, et al. Treatment of ulcerative colitis with oral 5-aminosalicyclic acid in patients unable to take sulphasalazine. Lancet 1983;2:801.
8. Turunen U, Elomaa I, Anttila VJ, et al. Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides. Scand J Gastroenterol 1987;22:798-802.
9. Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. Scand J Gastroenterol 1987;22:332-6.